Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders.

Trial Profile

Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders.

Not stated
Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs Rivogenlecleucel (Primary)
  • Indications Haemoglobinopathies; Immunodeficiency disorders; Leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors Bellicum Pharmaceuticals
  • Most Recent Events

    • 10 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top